CAR T-Cell Therapy for Pediatric ALL The University of Chicago Medicine is among the first sites in the Midwest certified to offer chimeric antigen receptor T-cell, or CAR T-cell, therapy for pedi- atric acute lymphoblastic leuke- mia (ALL), which was approved in August by the U.S. Food and Drug Administration. Used to supplement forms of can- cer treatment like chemotherapy, radiation and stem cell transplants, CAR T-cell therapy works by using modified versions of a patient’s own blood cells to target and destroy cancer cells. “CAR T-cell therapy has rev- olutionized the treatment of acute lymphoblastic leukemia,” according to cancer special- ist John Cunningham, MD, chair of pediatrics at the University of Chicago and physician-in-chief at Comer Children’s Hospital. “I came to the United States 30 years ago with the intent to work on thera- pies such as this. We need focused treatments like this that can eradi- cate particular types of cancer.” Pediatric ALL is a rapidly pro- gressive leukemia that primarily affects children and young adults, from age 3 to 25. Nearly 3,100 patients under 21 years old in the U.S. will be diagnosed with ALL this year. Ninety percent (20 out of 22) of pediatric patients with ALL enrolled in early CAR T-cell clinical trials throughout the coun- try went into lasting remission. Read more on page 14. 90% of pediatric  patients with ALL  enrolled in early CAR T-cell clinical trials throughout the country went into lasting remission. Dr. John Cunningham with Sam Tinaglia, who underwent CAR T-cell therapy 33